Price (delayed)
$33.14
Market cap
$1.86B
P/E Ratio
29.33
Dividend/share
N/A
EPS
$1.13
Enterprise value
$1.77B
Supernus Pharmaceuticals, Inc. is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The Company markets Trokendi XR® (extended-release topiramate) for
There are no recent dividends present for SUPN.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.